| Market Cap | 738.02M | P/E | - | EPS this Y | -8.50% | Ern Qtrly Grth | - |
| Income | -109.89M | Forward P/E | -5.13 | EPS next Y | -17.50% | 50D Avg Chg | 2.00% |
| Sales | 20.22M | PEG | 0.25 | EPS past 5Y | - | 200D Avg Chg | 15.00% |
| Dividend | N/A | Price/Book | 2.52 | EPS next 5Y | -15.90% | 52W High Chg | -32.00% |
| Recommedations | 1.80 | Quick Ratio | 27.93 | Shares Outstanding | 51.97M | 52W Low Chg | 236.00% |
| Insider Own | 3.48% | ROA | -16.86% | Shares Float | 26.40M | Beta | 2.79 |
| Inst Own | 112.50% | ROE | -24.06% | Shares Shorted/Prior | 9.52M/9.95M | Price | 17.89 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 551,431 | Target Price | 50.00 |
| Oper. Margin | -849,120.00% | Earnings Date | Nov 7 | Volume | 396,220 | Change | 0.39% |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| Cantor Fitzgerald | Neutral | Sep 23, 24 |
| Chardan Capital | Buy | Sep 19, 24 |
| Leerink Partners | Outperform | Sep 19, 24 |
| HC Wainwright & Co. | Buy | Sep 19, 24 |
| Cantor Fitzgerald | Overweight | Sep 9, 24 |
| HC Wainwright & Co. | Buy | Aug 9, 24 |
| RBC Capital | Outperform | Jul 22, 24 |
| BMO Capital | Outperform | Jul 18, 24 |
| Chardan Capital | Buy | Jul 17, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kirn David | Chief Executive Offi.. Chief Executive Officer | Jan 23 | Sell | 18.4079 | 5,696 | 104,851 | 1,151,154 | 01/25/24 |
| VIKING GLOBAL INVESTORS LP | 10% Owner 10% Owner | Jan 04 | Sell | 19.53 | 540,000 | 10,546,200 | 4,247,914 | 01/05/24 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Jun 08 | Sell | 20.85 | 3,750 | 78,188 | 1,737 | 06/12/23 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Jun 08 | Option | 8.04 | 3,750 | 30,150 | 5,487 | 06/12/23 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Jun 01 | Sell | 18.31 | 2,247 | 41,143 | 1,737 | 06/06/23 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Jun 01 | Option | 6.49 | 1,875 | 12,169 | 3,984 | 06/06/23 |
| Moretti August J | Chief Financial Offi.. Chief Financial Officer | May 15 | Option | 9.41 | 3,000 | 28,230 | 11,045 | 05/16/23 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Apr 21 | Sell | 20 | 3,750 | 75,000 | 2,109 | 04/25/23 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Apr 21 | Option | 8.04 | 3,750 | 30,150 | 5,859 | 04/25/23 |
| Chacko Jacob | Director Director | Apr 21 | Sell | 20.05 | 5,000 | 100,250 | 04/25/23 | |
| Chacko Jacob | Director Director | Apr 21 | Option | 9.41 | 5,000 | 47,050 | 5,000 | 04/25/23 |
| Kirn David | Chief Executive Offi.. Chief Executive Officer | Feb 21 | Sell | 20.88 | 34,446 | 719,232 | 1,859,153 | 02/23/23 |
| Kirn David | Chief Executive Offi.. Chief Executive Officer | Jan 19 | Sell | 20.11 | 19,524 | 392,628 | 1,893,599 | 01/23/23 |
| Moretti August J | Chief Financial Offi.. Chief Financial Officer | Dec 21 | Option | 9.41 | 3,000 | 28,230 | 6,595 | 12/22/22 |
| Kirn David | Chief Executive Offi.. Chief Executive Officer | Dec 15 | Sell | 23.44 | 86,877 | 2,036,397 | 1,913,123 | 12/19/22 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Dec 01 | Option | 7.27 | 5,625 | 40,894 | 6,607 | 12/05/22 |
| Bizily Scott | Chief Legal and HR O.. Chief Legal and HR Officer | Dec 01 | Sell | 23.22 | 6,000 | 139,320 | 2,482 | 12/05/22 |
| SCHAFFER DAVID | Director Director | Oct 20 | Sell | 31.19 | 36,285 | 1,131,729 | 901,215 | 10/22/21 |